[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity

Rhea-AI Filing Summary

Protagonist Therapeutics director William D. Waddill sold 4,000 shares of Protagonist Therapeutics, Inc. (PTGX) common stock on 09/22/2025 at a price of $64.25 per share, leaving him with 5,130 shares beneficially owned following the transaction. The sale was executed under a Rule 10b5-1 trading plan that the reporting person adopted on November 10, 2023. The Form 4 was signed on behalf of Mr. Waddill by an attorney-in-fact on 09/24/2025. The filing reports the transaction as a non-derivative disposition by a director and indicates the Form was filed by one reporting person.

Positive

• Sale executed under a disclosed Rule 10b5-1 trading plan, indicating pre-arranged compliance with insider trading rules
• Timely Form 4 filing executed and signed by an attorney-in-fact within two days of the transaction date

Negative

• Director ownership reduced by 4,000 shares, leaving 5,130 shares beneficially owned after the sale

Insights

Corporate Governance Expert

TL;DR: Director sold shares under a pre-established Rule 10b5-1 plan; filing appears routine and compliant.

The disclosure shows a director-initiated sale of 4,000 common shares at $64.25 on 09/22/2025 executed pursuant to a Rule 10b5-1 plan adopted 11/10/2023. Reporting via Form 4 was completed and signed by an attorney-in-fact, which is standard practice. This is a straightforward insider disposition rather than a change in control or compensation structure. The filing does not disclose any new agreements or departures and contains only the single non-derivative sale and the post-transaction beneficial ownership figure of 5,130 shares.

Securities Analyst

TL;DR: Transaction is a director sale under an existing trading plan; the filing supplies clear quantities and price.

The Form 4 reports a sale of 4,000 shares at $64.25, with remaining beneficial ownership of 5,130 shares. The sale is attributed to a previously adopted Rule 10b5-1 plan (11/10/2023), which typically signals a pre-arranged disposition schedule. There are no derivative transactions, grants, or acquisitions reported. From a disclosure perspective, the document provides the essential data points investors and compliance teams expect from an insider sale filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Waddill William D.

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		S(1)		4,000	D	$64.25	5,130	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.

	/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did William D. Waddill report on Form 4 for PTGX?

He reported selling 4,000 shares of Protagonist Therapeutics common stock on 09/22/2025 at $64.25 per share and owning 5,130 shares after the sale.

Was the sale by the PTGX director part of a trading plan?

Yes. The Form 4 states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2023.

When was the Form 4 for the PTGX transaction signed and filed?

The signature on the Form 4 is dated 09/24/2025 and executed by an attorney-in-fact for William D. Waddill.

Does the Form 4 report any derivative transactions for PTGX by this reporting person?

No. The filing contains only a non-derivative sale of common stock and no derivative securities reported.

How many shares does the reporting person own after the transaction?

5,130 shares beneficially owned following the reported sale.